275,313 Shares in Insulet Corporation $PODD Purchased by Jupiter Topco LLC

Jupiter Topco LLC purchased a new stake in shares of Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 275,313 shares of the medical instruments supplier’s stock, valued at approximately $41,917,000.

A number of other large investors also recently bought and sold shares of PODD. Larson Financial Group LLC boosted its position in Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Insulet during the 4th quarter valued at approximately $26,000. Elyxium Wealth LLC purchased a new position in shares of Insulet during the 4th quarter valued at approximately $28,000. DV Equities LLC acquired a new position in shares of Insulet in the 4th quarter valued at $28,000. Finally, MV Capital Management Inc. acquired a new position in shares of Insulet in the 4th quarter valued at $29,000.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Wall Street’s outlook remains a potential support for Insulet, with the latest analyst discussion examining whether the company’s long-term growth prospects and Omnipod franchise can outweigh recent execution concerns. Is Wall Street bullish or bearish on Insulet stock?
• Neutral Sentiment: Insulet said it will participate in the Wells Fargo 21st Annual Healthcare Conference, giving investors an opportunity to hear directly from management about demand, manufacturing, product quality and financial guidance. The event could become a catalyst if management provides reassuring updates, but no new information was disclosed in the announcement. Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: A former Insulet global customer-experience executive, Curtis Kopf, was appointed to a similar leadership role at Kestra Medical Technologies. The move is not a financial update for Insulet, although investors may monitor whether it affects customer-support or digital-transformation initiatives. Kestra Medical Technologies Names Curtis Kopf Senior Vice President of Customer Experience
• Negative Sentiment: Several firms, including Rosen, Bronstein Gewirtz & Grossman, SBS, DJS and others, are seeking investors to serve as lead plaintiff in a securities-fraud lawsuit against Insulet and certain officers. The complaints allege that the company made misleading statements or failed to disclose manufacturing and quality-control problems, including risks associated with Omnipod corrections. The allegations have not been proven, but the litigation creates potential legal costs, reputational damage and regulatory uncertainty. Rosen Insulet securities class-action notice

Wall Street Analyst Weigh In

PODD has been the subject of a number of analyst reports. Piper Sandler decreased their price objective on shares of Insulet from $360.00 to $210.00 in a research report on Wednesday, May 6th. UBS Group cut their price target on Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a research note on Thursday, August 6th. Sanford C. Bernstein reduced their price target on Insulet from $200.00 to $175.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Evercore set a $180.00 price target on Insulet in a research report on Monday, July 6th. Finally, Oppenheimer lowered Insulet from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Fourteen research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $195.40.

Insulet Stock Performance

PODD opened at $143.41 on Friday. The firm’s fifty day simple moving average is $154.47 and its two-hundred day simple moving average is $181.40. Insulet Corporation has a 52-week low of $126.40 and a 52-week high of $354.88. The company has a market cap of $9.95 billion, a price-to-earnings ratio of 26.81, a PEG ratio of 1.13 and a beta of 1.10. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. During the same quarter in the previous year, the company earned $1.17 earnings per share. The company’s quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities analysts anticipate that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of the business’s stock in a transaction on Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.36% of the company’s stock.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.